StartUPDATES: New developments for healthcare startups
Read about new developments from Stellar Health, Paige, venBio, and more.
venBio closes third fund for biopharma startup investment, valued at $394M
The San Francisco-based venture capital firm has recently led or participated in Series B and Series C funds of companies developing therapies in diseases like cancers and NASH.
Health Executives on Digital Transformation in Healthcare
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
ALX Oncology raises $105M in Series C round for checkpoint inhibitor development
The company is working to move its CD47-targeting drug, ALX148, into Phase II development. Another company, Forty Seven, is also developing a CD47-targeting therapy. CD47 is an immune checkpoint distinct from the ones targeted by currently marketed cancer immunotherapy drugs.
A $2B oncology deal goes bust at the hands of an activist investor
Activist investor venBio had a good Friday. Seattle Genetics and Immunomedics did not. The two latter companies agreed to fold on their $2 billion oncology deal, while Immunomedics' CEO and CSO also forfeited their jobs.